The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Drug discovery and development for neglected diseases: the DNDi model
Open accessAbstract
New models of drug discovery have been developed to overcome the lack of modern and effective drugs for neglected diseases such as human African trypanosomiasis (HAT; sleeping sickness), leishmaniasis, and Chagas disease, which have no financial viability for the pharmaceutical industry. With the purpose of combining the skills and research capacity in academia, pharmaceutical industry, and contract researchers, public-private partnerships or product development partnerships aim to create focused research consortia that address all aspects of drug discovery and development. These consortia not only emulate the projects within pharmaceutical and biotechnology industries, eg, identification and screening of libraries, medicinal chemistry, pharmacology and pharmacodynamics, formulation development, and manufacturing, but also use and strengthen existing capacity in disease-endemic countries, particularly for the conduct of clinical trials. The Drugs for Neglected Diseases initiative (DNDi) has adopted a model closely related to that of a virtual biotechnology company for the identification and optimization of drug leads. The application of this model to the development of drug candidates for the kinetoplastid infections of HAT, Chagas disease, and leishmaniasis has already led to the identification of new candidates issued from DNDi's own discovery pipeline. This demonstrates that the model DNDi has been implementing is working but its DNDi, neglected diseases sustainability remains to be proven.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
“Manifesto” for Advancing the Control and Elimination of Neglected Tropical Diseases
Hotez, P. J., & Pecoul, B. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000718 · Cited by 138
Cited by
Drug repurposing and human parasitic protozoan diseases
Andrews, K. T., Fisher, G., & Skinner-Adams, T. S. (2014) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.02.002 · Cited by 383
Chagas Disease Drug Discovery: Toward a New Era
Chatelain, E. (2015) · SLAS Discovery · doi:10.1177/1087057114550585 · Cited by 312
Management of trypanosomiasis and leishmaniasis
Barrett, M. P., & Croft, S. L. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds031 · Cited by 304
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L. (2012) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2012.01.003 · Cited by 294
Metadata
- Authors
- Ioset, J.-R., & Chatelain
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-03
- Volume
- 5
- Pages
- 175
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1975654905
- Cited by
- 182
- References
- 1
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug discovery and development for neglected diseases: the DNDi model. https://app.cochat.ai/papers/10.2147/dddt.s16381
- The paper
- Ioset, J.-R., & Chatelain. (2011). Drug discovery and development for neglected diseases: the DNDi model. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s16381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.